INT34009

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1983
Last Reported 2010
Negated 4
Speculated 0
Reported most in Abstract
Documents 33
Total Number 55
Disease Relevance 17.98
Pain Relevance 8.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Tbxa2r) plasma membrane (Tbxa2r) signal transducer activity (Tbxa2r)
Anatomy Link Frequency
platelet 18
plasma 3
leucocyte 1
leg 1
vascular endothelium 1
Tbxa2r (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 341 100.00 Very High Very High Very High
antagonist 115 99.96 Very High Very High Very High
cINOD 87 99.84 Very High Very High Very High
aspirin 334 99.76 Very High Very High Very High
Pain 64 99.76 Very High Very High Very High
COX2 15 99.28 Very High Very High Very High
Angina 27 99.08 Very High Very High Very High
cva 17 97.32 Very High Very High Very High
Inflammation 444 96.96 Very High Very High Very High
Kinase C 34 94.32 High High
Disease Link Frequency Relevance Heat
Hemorrhage 23 99.86 Very High Very High Very High
Pain 63 99.76 Very High Very High Very High
Sepsis 87 99.68 Very High Very High Very High
Leg Ulcer 3 99.48 Very High Very High Very High
Cv General 3 Under Development 40 99.08 Very High Very High Very High
Bacterial Infection 40 99.00 Very High Very High Very High
Natriuresis 2 98.68 Very High Very High Very High
Bacteremia 3 98.56 Very High Very High Very High
Increased Venous Pressure Under Development 92 98.52 Very High Very High Very High
Syndrome 2 98.10 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Unstable angina may be a clinical syndrome in which these events occur, which can be alleviated by inhibition of platelet activation and TXA2 formation with aspirin.
TXA2 Binding (formation) of in platelet associated with aspirin, angina and syndrome
1) Confidence 0.36 Published 1987 Journal Fed. Proc. Section Abstract Doc Link 3100342 Disease Relevance 0.45 Pain Relevance 0.15
Aspirin affords cardioprotection through inhibition of TxA2 formation by platelet cyclooxygenase (COX-1).
TxA2 Binding (formation) of in platelet associated with aspirin
2) Confidence 0.36 Published 2002 Journal Science Section Abstract Doc Link 11964481 Disease Relevance 0.16 Pain Relevance 0.13
This exaggerated vasoconstrictor response was associated with elevated TxA2 resting levels in plasma and with increased TxA2 synthesis after the cold pressor test.
TxA2 Binding (associated) of in plasma
3) Confidence 0.32 Published 1986 Journal Circulation Section Abstract Doc Link 3948351 Disease Relevance 0.86 Pain Relevance 0.55
Platelet activation, with subsequent formation of thromboxane A2 (TxA2), is thought to play a role in the development of arterial occlusion.
thromboxane A2 Binding (formation) of in Platelet
4) Confidence 0.32 Published 1988 Journal Clin Physiol Section Abstract Doc Link 3402185 Disease Relevance 0.42 Pain Relevance 0.16
In patients with severe atherosclerosis of the lower limbs, characterized by leg ulcers and rest pain, the basal formation of TxA2 and prostacyclin (PGI2) is increased.
TxA2 Binding (formation) of in leg associated with pain, leg ulcer and increased venous pressure under development
5) Confidence 0.32 Published 1988 Journal Clin Physiol Section Abstract Doc Link 3402185 Disease Relevance 0.53 Pain Relevance 0.24
Platelet activation, with subsequent formation of thromboxane A2 (TxA2), is thought to play a role in the development of arterial occlusion.
TxA2 Binding (formation) of in Platelet
6) Confidence 0.32 Published 1988 Journal Clin Physiol Section Abstract Doc Link 3402185 Disease Relevance 0.42 Pain Relevance 0.16
Plasma TXB2 and 6-keto-PGF1 alpha were measured as stable metabolites of TXA2 and PGI2, respectively, by radioimmunoassay.
TXA2 Binding (metabolites) of in Plasma
7) Confidence 0.32 Published 1983 Journal Am. Heart J. Section Abstract Doc Link 6344604 Disease Relevance 0.44 Pain Relevance 0.05
Interaction of thromboxane A2 and tissue pathology during graded bacteremia.
thromboxane A2 Binding (Interaction) of associated with bacteremia
8) Confidence 0.31 Published 1987 Journal J Trauma Section Title Doc Link 3820352 Disease Relevance 0.35 Pain Relevance 0.31
TxA2 formation occurs mainly in extravascular spaces, probably within the coronary vascular wall.
TxA2 Binding (formation) of
9) Confidence 0.31 Published 1994 Journal Coron. Artery Dis. Section Body Doc Link 8180744 Disease Relevance 0 Pain Relevance 0
Present results indicate that in platelets from anginal patients phospholipid fatty acid composition is at least in part independent of plasma composition and that in active angina there are modifications leading to increased TxA2 formation and possibly contributing to the occurrence of ischemic attacks.
TxA2 Binding (formation) of in plasma associated with angina
10) Confidence 0.31 Published 1986 Journal Thromb. Res. Section Abstract Doc Link 3024352 Disease Relevance 0.46 Pain Relevance 0.46
Other pharmacological studies demonstrated that picotamide binding to thromboxane A2 receptors is initially reversible and becomes progressively non-displaceable (Modesti et al 1991, 1994).
thromboxane A2 Binding (binding) of
11) Confidence 0.29 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 0.15 Pain Relevance 0.07
Trapidil has shown a more complete antithrombocytic activity than other antiaggregating drugs; as a matter of fact it inhibits the formation of TXA2 through a mechanism of receptorial antagonism and at the same time it favours an increase of prostacyclina from the arterial walls.
TXA2 Binding (formation) of
12) Confidence 0.28 Published 1993 Journal Minerva Cardioangiol Section Abstract Doc Link 8373465 Disease Relevance 0.28 Pain Relevance 0.09
Vasoconstrictors include endothelin-1 (ET-1), angiotensin II (Ang II), thromboxane A2 (TXA2), and reactive oxygen species (ROS).
thromboxane A2 Binding (include) of
13) Confidence 0.28 Published 2005 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993938 Disease Relevance 0.94 Pain Relevance 0.09
Vasoconstrictors include endothelin-1 (ET-1), angiotensin II (Ang II), thromboxane A2 (TXA2), and reactive oxygen species (ROS).
TXA2 Binding (include) of
14) Confidence 0.28 Published 2005 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993938 Disease Relevance 0.94 Pain Relevance 0.12
H2O2 exposure attenuates ligand-induced internalization of the thromboxane receptor
thromboxane receptor Binding (internalization) of
15) Confidence 0.25 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2939892 Disease Relevance 0 Pain Relevance 0.05
They do not reduce the formation of the COX-1-derived thromboxane A2 (TXA2), however, which is both atherogenic and a potent vasoconstrictor.
TXA2 Neg (not) Binding (formation) of
16) Confidence 0.23 Published 2005 Journal Trends Endocrinol. Metab. Section Abstract Doc Link 15950485 Disease Relevance 0.42 Pain Relevance 0.22
Their effects in activating platelets are mediated by receptors closely related to TxA2 receptors and may be potentially counteracted by TxA2 receptor antagonists such as picotamide.
TxA2 receptor Binding (counteracted) of in platelets associated with antagonist
17) Confidence 0.22 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994050 Disease Relevance 1.07 Pain Relevance 0.20
In contrast, when COX2 is inhibited selectively, platelet aggregation by TxA2 is intact, but at the same time PGI2 induced platelet deaggregation is compromised, resulting in enhanced platelet aggregation [57].
TxA2 Binding (aggregation) of in platelet associated with cox2
18) Confidence 0.22 Published 2006 Journal Mol Pain Section Body Doc Link PMC1563450 Disease Relevance 0.85 Pain Relevance 0.55
The AA can then be metabolized and converted to prostanoids, such as prostacyclin (PGI2), which is a strong smooth muscle relaxant, prostaglandin G, which is a constrictor, thromboxane A2 (TXA2), or to leukotrienes (LT), which cause the adherence of leukocytes to vascular endothelium.
thromboxane A2 Binding (metabolized) of in vascular endothelium
19) Confidence 0.22 Published 2010 Journal Korean Journal of Anesthesiology Section Body Doc Link PMC2946038 Disease Relevance 0.34 Pain Relevance 0.07
They do not reduce the formation of the COX-1-derived thromboxane A2 (TXA2), however, which is both atherogenic and a potent vasoconstrictor.
thromboxane A2 Neg (not) Binding (formation) of
20) Confidence 0.20 Published 2005 Journal Trends Endocrinol. Metab. Section Abstract Doc Link 15950485 Disease Relevance 0.42 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox